OLMA news

Latest 2 stories · newest May 26, 2026

OLMA

Olema partners with Bayer to study OP-3136 with darolutamide in prostate cancer

Olema Pharmaceuticals announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with Bayer's darolutamide in metastatic castration-resistant prostate cancer patients, with the Phase 1b/2 study expected to initiate in H2 2026. The partnership marks the …

Other May 26, 2026 sentiment +0.65 SEC filing ↗

OLMA

Olema's OP-3136 KAT6 inhibitor shows promising Phase 1 data with good tolerability.

Olema Pharmaceuticals announced encouraging initial clinical data from Phase 1 testing of OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities and tumor shrinkage in two-thirds of patients. The positive safety and efficacy findings support continued development as monotherapy and in combin…

Regulatory May 21, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same OLMA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/OLMA/newsSTART FREE